The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Amid a wave of consolidation in the life sciences sector, Germany's Merck KGaA announced it will acquire Bio-Techne in an all-cash deal valued at $11.3 billion, according to financial reports. The 24% premium over the pre-announcement share price sent Bio-Techne's stock sharply higher. The transaction is subject to customary regulatory approvals.
The acquisition fits Merck's strategy to expand its laboratory tools and diagnostics capabilities. Per market data, Merck's OTC stock (MKKGY) closed at $31.85 on June 24, 2026, while Bio-Techne's market capitalization stood at roughly $9.1 billion before the premium. This is Merck's largest acquisition in years, underscoring management's confidence in growth prospects.
Sign in to access this content
Sign InInvestors are monitoring the deal's progression and its impact on MKKGY, which traded between $31.37 and $31.92 on the day. Markets are also watching central bank meetings and upcoming Fed speeches this week, which could influence financing costs for the acquisition.